Benutzerspezifische Werkzeuge

Ongoing Research Projects

 

Prostate cancer (PCa)

  • Diagnosis and prognosis of PCa by gene expression analyses
    • Identification of genes and gene signatures which are differentially expressed in tumor versus non-malignant prostate tissues: Is it possible to predict the presence of tumor cells in a prostate tissue sample by measuring the expression levels of the identified genes?
    • Evaluation of the identified markers for diagnosis and prognosis in biopsy tissues and urine of PCa patients
  • microRNA-mediated regulation of PCa-associated genes
    • Do microRNAs regulate the expression of selected PCa-associated genes?

Bladder cancer (BCa)

  • Establishment of an orthotopic BCa xenograft model in mice for the testing of anticancer drugs
  • Gene knock-down by antisense oligonucleotides and siRNAs in combination with chemotherapy and/or carbon nanotubes in vitro and in BCa xenograft mouse models
    • Is it possible to reduce BCa cell growth by the selective inhibition of tumor-associated genes with antisense oligonucleotides or siRNAs?
    • Is the combined inhibition of different targets more effective in reducing tumor growth than the knockdown of a single target gene?
    • Does the specific gene inhibition cause chemosensitization?
    • Does the combined treatment of BCa cells with chemotherapeutics and carbon nanotubes increase the chemotherapy efficiency?
    • Is it possible to further increase the chemotherapy efficiency by simultaneous application of target-specific antisense oligonucleotides and carbon nanotubes?
  • Improvement of non-invasive BCa diagnosis
    • Is the quantification of BCa associated transcripts or proteins a feasible non-invasive assay to complement cytology?

Renal cell carcinoma (RCC)

  • Identification and evaluation of prognostic protein markers on tissue microarrays of primary and metastasized RCC
    • Do proteins exist that are differentially expressed in malignant versus non-malignant renal tissues?
    • Is the expression of such markers associated with the prognosis of RCC patients?
    • Is there a correlation between the expression of these proteins and clinicopathological data?
  • Identification of molecular markers which predict the individual response of patients with metastasized RCC to targeted therapies
    • Are specific molecular characteristics of selected factors, e.g. gene expression, phosphorylation, copy number etc., related to patient’s response to targeted antiangiogenic therapies?

Multi-functional carbon nanoparticles for biomedical applications

    • Investigations on the biocompatibility and functionalization of carbon-based nanoparticles and nanotubes
    • Utilization of carbon nanotubes as carriers for chemotherapeutics and nucleic acid based agents in the treatment of bladder cancer
    • Modification of nanotubes with radiosensitizing compounds